Navigation Links
Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
Date:4/15/2011

IRVINE, Calif., April 15, 2011 /PRNewswire/ -- Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative high technology company announced today that critical intellectual property for Shrink's Cell Align™ cell culturing and tissue engineering material, along with a novel higher performing immunoassay substrate has been filed with the US Patent & Trademark Office.

Cell Align is a micro-fabricated substrate with non-periodic (or random) linear patterned grooves that allow for the alignment of cells along a single axis. The unique design is ideal for growing biological tissues from stem cells, especially those that naturally grow in a linear fashion such as in cardiac and nerve tissues.

Shrink CEO Mark L. Baum stated, "Our team is pleased with the recent filings for our Cell Align product portfolio, as well as the filing made for our novel immunoassay substrate.  These filings mean that, from an intellectual property perspective, we are able to move into multiple versions of, for example, the Cell Align product, using a scalable manufacturing process and a material that performs better than materials we formerly worked with.  As we plan our go-to-market strategy for Cell Align, because of this new IP, the materials we use and the manufacturing process we employ will deliver a better product to end-users, and from our shareholders' perspective, they deliver better value and profit potential."

"A large potential market for our new patent-pending material is as a substrate in immunoassays.  Shrink has been working in this space for two years, and we believe that the materials we are now working with perform better than any that we have used in the past.  Historically we have been able to show results that exceeded key parameters in performance, relative to existing immunoassay substrates.  Our objective is always to go head-to-head with existing market leading platforms and show that we are able to reduce the problematic 'noise' while maintaining a high signal.  We will continue to optimize our new patent pending material, and conduct additional tests, working towards collaborations and licensing opportunities with market leading immunoassay companies."

In the United States, tissue engineering and cell therapy comprised a $6.9 billion market for regenerative products in 2009, and is expected to approach $32 Billion by 2018, according to the 2010 MedMarket Diligence's Report, "Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018."  The report says the market for cellular therapies may benefit many disorders, including degenerative and traumatic orthopedic and spine injuries, cardiac and vascular disease, neurological disorders, diabetes, inflammatory diseases, and tooth decay.

About Shrink Nanotechnologies, Inc.

Shrink Nanotechnologies, Inc. is a FIGA™ organization, focusing on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink licenses, owns and in all cases develops proprietary and patent-pending nano-sized technologies, components and product systems for a number of leading edge technology markets of varying sizes. For more information, please visit www.shrinknano.com.

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release due to a myriad of factors given the stage of development of Shrink. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Shrink is a development stage company and any investment in Shrink should only be made after (i) review of our public filings with the U.S. Securities and Exchange Commission (www.sec.gov), particularly the "Risk Factors" in our most recent Form 10-K, and (ii) after counsel from a registered investment professional.

Contact:

For Shrink Nanotechnologies
Mark L. Baum
760-692-1160

(Logo: http://photos.prnewswire.com/prnh/20101015/SHRINKLOGO)


'/>"/>
SOURCE Shrink Nanotechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells
2. Seniors Shortchanged on Time as Annual Enrollment Period Shrinks This Fall
3. Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas
4. New Cancer Treatment Shrinks Pancreatic Tumor
5. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That Sea of Troubles
8. Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE
9. ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at the SAWC/WHS National Wound Symposium
10. LifeVantage Announces Preliminary Third Quarter 2011 Revenue
11. Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., ... pleased to announce the appointment of George M. Rapier, ... San Antonio, TX , WellMed is one of ... 200,000 patients and HMO members in Texas ... in 1990 out of his own internal medicine practice, he ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. ... utilizing human amniotic membrane and other birth tissues, human ... to develop and market advanced products and therapies, announced ... Markets, 2016 Global Healthcare Conference in New ... and CEO, Michael J. Senken , Chief Financial ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
(Date:2/11/2016)... ... 2016 , ... The Chartis Group, a national advisory services ... the “2015/2016 Best in KLAS: Software and Services” report in two categories: IT ... insights firm on a global mission to improve healthcare delivery by amplifying the ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... to reverse diabetes has been gearing up for their simultaneous grand openings in ... It’s about right now that you’re probably wondering, is reversing diabetes possible? According ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader ... to announce the promotions of Allison Kelly to executive vice president of the ... vice president of North American capital sales, and Wendy Oseas to vice president ...
Breaking Medicine News(10 mins):